CorMedix Inc. (CRMD) — Quarterly Report

Key Insights

• The filing is a Q1 2026 10-Q with a filing date of May 14, 2026, indicating CorMedix is reporting financial results for the quarter ended March 31, 2026, which appears to be recent and current.
• The XBRL data structure shows revenue recognition across multiple customer segments (Customer A, B, C) with detailed tracking of sales revenue and accounts receivable, suggesting the company maintains significant customer concentration that requires monitoring.
• The filing includes detailed fair value measurements for money market funds, marketable equity securities, and contingent consideration liabilities, indicating the company maintains investment portfolios and may have acquisition-related contingent obligations.
• Revenue recognition adjustments are tracked through volume incentive rebates, Medicaid and commercial rebates, distribution service fees, and prompt pay discounts, suggesting complex revenue dynamics typical of healthcare/medical device companies operating in a rebate-intensive environment.
• The presence of stock option and restricted stock unit data in the XBRL structure indicates ongoing equity compensation activity, reflecting typical biotech/medical device company compensation practices.